FI4054582T3 - Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon - Google Patents

Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon

Info

Publication number
FI4054582T3
FI4054582T3 FIEP20800617.1T FI20800617T FI4054582T3 FI 4054582 T3 FI4054582 T3 FI 4054582T3 FI 20800617 T FI20800617 T FI 20800617T FI 4054582 T3 FI4054582 T3 FI 4054582T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
combination
Prior art date
Application number
FIEP20800617.1T
Other languages
English (en)
Finnish (fi)
Inventor
Hannah Dry
Brandon Willis
Andrew Bloecher
Jerome Mettetal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI4054582T3 publication Critical patent/FI4054582T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FIEP20800617.1T 2019-11-04 2020-10-30 Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon FI4054582T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (1)

Publication Number Publication Date
FI4054582T3 true FI4054582T3 (fi) 2025-12-04

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20800617.1T FI4054582T3 (fi) 2019-11-04 2020-10-30 Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon

Country Status (14)

Country Link
US (1) US20220401442A1 (enExample)
EP (1) EP4054582B1 (enExample)
JP (1) JP7575454B2 (enExample)
KR (1) KR20220098175A (enExample)
CN (1) CN114728003B (enExample)
AU (1) AU2020381240C1 (enExample)
CA (1) CA3158321A1 (enExample)
DK (1) DK4054582T3 (enExample)
ES (1) ES3055126T3 (enExample)
FI (1) FI4054582T3 (enExample)
MX (1) MX2022005250A (enExample)
PL (1) PL4054582T3 (enExample)
PT (1) PT4054582T (enExample)
WO (1) WO2021089419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
KR20250105657A (ko) * 2022-11-15 2025-07-08 아스트라제네카 아베 카피바설팁과 베네토클락스의 치료적 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
EP3689878B1 (en) 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
KR20160090903A (ko) * 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
CN105979948A (zh) * 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
US20180353512A1 (en) * 2015-06-23 2018-12-13 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
CU20180059A7 (es) * 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2019058348A1 (en) * 2017-09-25 2019-03-28 Astrazeneca Ab COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合

Also Published As

Publication number Publication date
CN114728003B (zh) 2025-01-28
DK4054582T3 (da) 2025-12-01
US20220401442A1 (en) 2022-12-22
WO2021089419A1 (en) 2021-05-14
ES3055126T3 (en) 2026-02-10
PL4054582T3 (pl) 2026-02-16
CA3158321A1 (en) 2021-05-14
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
EP4054582B1 (en) 2025-09-03
PT4054582T (pt) 2025-12-10
CN114728003A (zh) 2022-07-08
EP4054582A1 (en) 2022-09-14
AU2020381240B2 (en) 2023-09-07
AU2020381240A1 (en) 2022-06-23
AU2020381240C1 (en) 2024-02-15
MX2022005250A (es) 2022-06-08
KR20220098175A (ko) 2022-07-11

Similar Documents

Publication Publication Date Title
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
RU2014141362A (ru) Комбинированная терапия пролиферативных нарушений
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
RU2011102797A (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
RU2010151952A (ru) Водорастворимые аналоги ацетаминофена
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
JP2011529968A5 (enExample)
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
FI4054582T3 (fi) Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon
WO2017106714A1 (en) Methods and compositions for treating peripheral neuropathy
JP2024542984A5 (enExample)
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
ES2503540T3 (es) Composición farmacéutica que combina un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
MX2026001173A (es) Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов